Your browser doesn't support javascript.
loading
A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
Cartee, Robert T; Thanawastien, Ann; Griffin Iv, Thomas J; Mekalanos, John J; Bart, Stephan; Killeen, Kevin P.
Afiliação
  • Cartee RT; Matrivax Research & Development Corporation, Boston, MA, United States of America.
  • Thanawastien A; Matrivax Research & Development Corporation, Boston, MA, United States of America.
  • Griffin Iv TJ; Matrivax Research & Development Corporation, Boston, MA, United States of America.
  • Mekalanos JJ; Department of Microbiology, Harvard Medical School, Boston MA, United States of America.
  • Bart S; Trial Professionals Consulting Group Inc., Woodstock, MD, United States of America.
  • Killeen KP; Matrivax Research & Development Corporation, Boston, MA, United States of America.
PLoS Negl Trop Dis ; 14(1): e0007912, 2020 01.
Article em En | MEDLINE | ID: mdl-31905228
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Febre Tifoide / Vacinas Tíficas-Paratíficas / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Febre Tifoide / Vacinas Tíficas-Paratíficas / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article